# A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

> **NCT00954590** · PHASE3 · TERMINATED · sponsor: **Medivation, Inc.** · enrollment: 89 (actual)

## Conditions studied

- Moderate to Severe Alzheimer

## Interventions

- **DRUG:** Dimebon (latrepirdine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00954590
- **Lead sponsor:** Medivation, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2016-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954590, "A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00954590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*